Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

[Locally advanced granulocyte colony-stimulating factor-producing non-small cell lung cancer successfully treated with concurrent chemoradiotherapy].

Yokosuka T, Enomoto T, Takeda A, Kobayashi T.

Gan To Kagaku Ryoho. 2013 Nov;40(12):2330-2. Japanese.

PMID:
24394102
2.

Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.

Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-89-S12-95.

PMID:
9331129
3.

Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.

Scagliotti GV, Ricardi U, Crinó L, Maranzano E, De Marinis F, Morandi MG, Meacci L, Marangolo M, Emiliani E, Rosti G, Figoli F, Bolzicco G, Masiero P, Gentile A, Tonato M.

Cancer Chemother Pharmacol. 1996;38(6):561-5.

PMID:
8823499
4.
5.
6.

Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.

Takayama K, Inoue K, Tokunaga S, Matsumoto T, Oshima T, Kawasaki M, Imanaga T, Kuba M, Takeshita M, Harada T, Shioyama Y, Nakanishi Y.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1353-9. doi: 10.1007/s00280-013-2335-2.

PMID:
24166107
7.

[Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].

Wang J, Pang QS, Wang P, Wang J, Wang W.

Zhonghua Zhong Liu Za Zhi. 2007 Oct;29(10):769-72. Chinese.

PMID:
18396691
8.

[A case of large cell carcinoma of the lung which is suspected of producing granulocyte colony-stimulating factor].

Teramachi M, Miyamoto N, Yamamoto Y, Sasaka T, Nakamura T, Kitamura F.

Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Jul;30(7):1327-32. Japanese.

PMID:
1383587
9.

Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.

Friedel G, Budach W, Dippon J, Spengler W, Eschmann SM, Pfannenberg C, Al-Kamash F, Walles T, Aebert H, Kyriss T, Veit S, Kimmich M, Bamberg M, Kohlhaeufl M, Steger V, Hehr T.

J Clin Oncol. 2010 Feb 20;28(6):942-8. doi: 10.1200/JCO.2008.21.7810.

PMID:
20100967
10.

[A case of large cell carcinoma of the lung producing granulocyte colony-stimulating factor].

Kasuga I, Yonemaru M, Minemura K, Utsumi K, Torii Y, Ichinose Y, Toyama K, Ebihara Y.

Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Jan;32(1):73-7. Japanese.

PMID:
7509424
11.

A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy.

Takagi Y, Nakamura H, Miwa K, Adachi Y, Fujioka S, Haruki T, Taniguchi Y.

Thorac Cardiovasc Surg. 2010 Aug;58(5):304-6. doi: 10.1055/s-0029-1240744.

PMID:
20680910
12.

Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.

Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, Kaiser LR.

J Thorac Cardiovasc Surg. 2004 Jan;127(1):108-13.

13.

Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.

Langer CJ, Leighton J, McAleer C, Comis R, O'Dwyer P, Ozols R.

Semin Oncol. 1995 Jun;22(3 Suppl 6):64-9.

PMID:
7541156
14.

Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.

Lan WG, Hao YZ, Xu DH, Wang P, Zhou YL, Ma LB.

Clin Transl Oncol. 2016 Apr;18(4):375-80. doi: 10.1007/s12094-015-1375-y.

PMID:
26329292
15.

Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.

Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-73-S12-80.

PMID:
9331127
16.

Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.

Cho JH, Kim J, Kim K, Shim YM, Kim HK, Choi YS.

World J Surg. 2012 May;36(5):1199-205. doi: 10.1007/s00268-012-1472-9.

PMID:
22374538
17.

[Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].

Mito A, Yamasaki M, Matsuura K, Kajihara T, Nitta T, Awaya H, Arita K, Kashiwado K, Ohashi N.

Gan To Kagaku Ryoho. 2009 Oct;36(10):1653-6. Japanese.

PMID:
19838022
19.

Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.

Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF.

Semin Oncol. 1995 Aug;22(4 Suppl 9):18-29.

PMID:
7544025
20.

Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.

Choi NC, Fischman AJ, Niemierko A, Ryu JS, Lynch T, Wain J, Wright C, Fidias P, Mathisen D.

Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1024-35.

PMID:
12419428

Supplemental Content

Support Center